 Decrease cerebral metabolic rate glucose high-dose methotrexate childhood acute lymphocytic leukemia changes regional cerebral metabolic rate glucose rCMRGlu positron emission tomography assessment neurotoxicity childhood acute lymphocytic leukemia high-dose methotrexate HD-MTX therapy children acute lymphocytic leukemia mean age years HD-MTX mg/kg therapy CMRGlu HD-MTX therapy reduced patient central nervous system leukemia total doses intrathecal MTX IT-MTX HD-MTX CMRGlu whole brain HD-MTX therapy average reductions CMRGlu patients total doses IT-MTX systemic HD-MTX CMRGlu cerebral cortex frontal occipital cortex basal ganglia white matter measurement changes rCMRGlu HD-MTX therapy useful MTX neurotoxicity